Amongst the eight members of the prostate cancer cohort who had exposure to antiandrogenic drugs, no effect of prior hormone treatment on the expression levels of LMTK2 was noted (0.49 [IQR 0.29) for untreated subjects versus 0.32 [IQR 0.30] in treated subjects; P = 0.270). This evidence concerns the gene LMTK2 and Familial prostate cancer.